Hello Navis. I was first diagnosed with prostate cancer, PSA about 4.0 ng/ml, in Dec., 2014 by MRI and fusion biopsy...

Thank you for sharing such a detailed and well-documented history. Your case illustrates several important clinical concepts, and I can help you understand where you stand and what to anticipate. Let me walk through this systematically.

YOUR CLINICAL JOURNEY - EDUCATIONAL SUMMARY

Initial Diagnosis & Recurrence Pattern: Your initial presentation (PSA 4.0, GG4 tumor) and subsequent recurrence after focal treatment represents what's called biochemical recurrence — when PSA rises after initial treatment, even though imaging may show organ-confined disease. The genomic findings (PTEN and P53 loss via Foundation One) are significant because these are tumor suppressor genes; their loss typically indicates more aggressive biology and can influence treatment selection.

Response to Multimodal Therapy: Your dramatic PSA response (nadiring to 0.03) after ADT + abiraterone + docetaxel + SBRT is an excellent clinical outcome. According to NCCN Guidelines for Advanced-Stage Prostate Cancer, this combination approach for metastatic hormone-sensitive disease (mHSPC) represents standard-of-care treatment. The January 2023 PSMA PET showing resolution of most bone mets confirms meaningful disease control.

Current Status - ADT Holiday: Your oncologist's decision to initiate an ADT holiday (treatment break) is clinically reasonable. This approach allows:

• Recovery from hormone therapy side effects
• Assessment of disease biology during the break
• Preservation of treatment options for future use

---

WHAT TO EXPECT GOING FORWARD

When PSA Rises Again (The Clinical Framework):

According to NCCN Guidelines for Advanced-Stage Prostate Cancer, when patients with your history experience PSA recurrence after excellent initial response, oncologists typically consider:

1. Speed of PSA rise — Your previous pattern (slow rise, then rapid acceleration) will be compared to new kinetics
2. PSMA PET imaging — To determine if metastatic disease has returned and where
3. Prior treatment exposure — You've already received ADT, abiraterone, and docetaxel
4. Genomic profile — Your PTEN/P53 loss may influence next-line options

Treatment Options That Typically Exist for Your Situation:

For patients with your genomic findings (PTEN/P53 loss) who've progressed after initial mHSPC therapy, the medical literature describes several approaches:

• Hormone-resistant prostate cancer (CRPC) therapies — Additional androgen pathway inhibitors (enzalutamide, darolutamide) or other mechanisms
• Chemotherapy options — Cabazitaxel (if docetaxel was tolerated) or other agents
• PARP inhibitors — Particularly relevant given your P53 loss; these drugs exploit DNA repair deficiencies
• Immunotherapy combinations — Emerging data in select CRPC populations
• Clinical trials — Novel agents or combinations targeting your specific mutations

---

SPECIFIC QUESTIONS TO ASK YOUR ONCOLOGIST NOW

Given your excellent response and upcoming PSA monitoring, I'd recommend discussing:

1. "What PSA level or doubling time would prompt you to restart treatment, and what imaging would you order?"

   • This clarifies your oncologist's threshold for intervention

2. "Given my PTEN and P53 loss, are there specific targeted therapies you're considering if my PSA rises again?"

   • This directly addresses your genomic findings and next-line options

3. "How would you sequence treatments if I progress — would you use another androgen pathway inhibitor, PARP inhibitor, or chemotherapy, and why?"

   • This helps you understand the clinical reasoning for sequencing

4. "Should I have another PSMA PET scan when my PSA reaches a certain level, or on a schedule?"

   • PSMA imaging is crucial for detecting early metastatic recurrence

5. "Are there clinical trials for CRPC with PTEN/P53 loss that might be appropriate for me?"

   • This ensures you're aware of cutting-edge options

6. "What side effects should I monitor during this ADT holiday, and when should I contact you?"

   • Practical guidance for the break period

---

IMPORTANT CLINICAL CONTEXT

Your case demonstrates what oncologists call oligometastatic disease with excellent chemosensitivity — meaning:

• Limited number of metastases (20 bone lesions is relatively limited)
• Dramatic response to multimodal therapy
• Potential for extended disease control with sequential treatments

According to NCCN Guidelines, patients with your response pattern and genomic profile may have multiple treatment options available, and the goal is to sequence them strategically to maintain quality of life while controlling disease.

---

YOUR PROGNOSIS QUESTION

I want to be direct about what I cannot do: I cannot provide a prognosis or survival estimate. That requires your oncologist's complete clinical assessment, including:

• Your age and overall health
• Exact extent of current disease
• Your tolerance of prior treatments
• Your personal goals and preferences

What I can say: Your excellent response to initial therapy, the resolution of most bone mets, and your genomic profile (while indicating aggressive biology) also suggests potential sensitivity to targeted approaches. This is genuinely favorable territory.

---

RECOMMENDED RESOURCES

For deeper understanding of your situation:

• NCCN Guidelines for Advanced-Stage Prostate Cancer (2024) — Specifically the sections on hormone-resistant treatment and CRPC management
• American Cancer Society's Prostate Cancer Information — For understanding treatment sequencing
• Cancer Commons — Offers genomic-guided treatment matching for cases like yours with PTEN/P53 loss

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Your oncologist has clearly managed your case thoughtfully. These questions should help you engage in shared decision-making as you move forward. Do you have questions about any specific treatment options or how to interpret future test results?